<DOC>
	<DOC>NCT00874744</DOC>
	<brief_summary>The purpose of this study is to compare a single intravitreal injection of 4.0 mg of triamcinolone acetonide and 1.25 mg of bevacizumab for the treatment of diabetic macular edema.</brief_summary>
	<brief_title>Comparison of Single Intravitreal Injection of Triamcinolone or Bevacizumab for the Treatment of Diabetic Macular Edema</brief_title>
	<detailed_description>Comparison a single intravitreal injection of 4.0 mg of triamcinolone acetonide and 1.25 mg of bevacizumab regarding the ability of central macular thickness reduction. Secondary objectives are analysis of Visual Outcomes and variations on Intraocular Pressure. The patients data were statistically analyzed if there was a 24 week follow up completed.</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Diabetic macular edema with central foveal measurement over 300 micrometers Glaucoma Vitreoretinal surgery Cataract Surgery less than 3 months prior inclusion Unilateral cataract surgery Uncontrolled Glycosylated Hemoglobin Previous Intraocular Injection Systemic Corticosteroids less than 1 month prior inclusion Macular ischemia at Fluorescein Angiography Cataract precluding fundus examination Active Proliferative Diabetic Retinopathy</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Diabetic macular edema</keyword>
	<keyword>intravitreal injection</keyword>
	<keyword>Pharmacological treatment</keyword>
</DOC>